In xenografted mice, CART-38-mediated rejection of acute myeloid leukemia, T cell acute lymphoblastic leukemia, and multiple myeloma cell lines and primary samples and prolonged survival.
[Blood Advances]
Home Newsletters Cell Therapy News CD38 as a Pan-Hematologic Target for Chimeric Antigen Receptor T Cells
